KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Net Income (2016 - 2025)

Ionis Pharmaceuticals has reported Net Income over the past 17 years, most recently at $151.8 million for Q4 2025.

  • Quarterly results put Net Income at $151.8 million for Q4 2025, up 244.54% from a year ago — trailing twelve months through Dec 2025 was -$207000.0 (up 99.95% YoY), and the annual figure for FY2025 was -$207000.0, up 99.95%.
  • Net Income for Q4 2025 was $151.8 million at Ionis Pharmaceuticals, up from -$128.6 million in the prior quarter.
  • Over the last five years, Net Income for IONS hit a ceiling of $224.6 million in Q4 2021 and a floor of -$147.4 million in Q3 2023.
  • Median Net Income over the past 5 years was -$83.9 million (2021), compared with a mean of -$56.0 million.
  • Biggest five-year swings in Net Income: surged 1450.73% in 2021 and later plummeted 1033.67% in 2024.
  • Ionis Pharmaceuticals' Net Income stood at $224.6 million in 2021, then crashed by 123.34% to -$52.4 million in 2022, then surged by 82.33% to -$9.3 million in 2023, then plummeted by 1033.67% to -$105.0 million in 2024, then skyrocketed by 244.54% to $151.8 million in 2025.
  • The last three reported values for Net Income were $151.8 million (Q4 2025), -$128.6 million (Q3 2025), and $123.6 million (Q2 2025) per Business Quant data.